Skip to main content
LigaChem Biosciences Inc. logo

LigaChem Biosciences Inc. — Investor Relations & Filings

Ticker · 141080 ISIN · KR7141080002 KO Professional, scientific and technical activities
Open in API
Filings indexed 295 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country KR South Korea
Listing KO 141080

About LigaChem Biosciences Inc.

https://ligachembio.com/

LigaChem Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative medicines. Leveraging its core expertise in medicinal chemistry, the company focuses on developing Antibody-Drug Conjugates (ADCs), immuno-oncology drugs, and small molecules. A key asset is its proprietary, next-generation ADC platform technology, engineered to overcome the limitations of conventional ADC technologies. The company's pipeline includes multiple programs targeting oncology, as well as other therapeutic areas such as antibiotics and anti-fibrotics. LigaChem Biosciences actively pursues global drug development through strategic partnerships, including co-development and licensing agreements with international pharmaceutical companies.

Recent filings

Filing Released Lang Actions
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
Regulatory Filings Classification · 85% confidence The document is a Korean corporate group status disclosure (기업집단현황공시) detailing affiliates, financials, officers, intra‐group transactions, and governance items required under local regulatory compliance. It is not an annual or interim financial report, not a notice of dividend or board change, and contains substantive regulatory‐mandated disclosures rather than simply announcing another report. It therefore falls under General Regulatory Filings (RNS).
2026-06-01 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is a Korean-language 분기보고서 (quarterly report) for the 21st fiscal year 1st quarter, dated January 1 to March 31, 2026. It contains detailed financial statements, business descriptions, sales figures, contracts, and asset tables, consistent with a comprehensive Interim/Quarterly Report. Therefore, it should be classified as an Interim / Quarterly Report (IR). Q1 2026
2026-05-15 Korean
[기재정정]기업설명회(IR)개최
Investor Presentation Classification · 91% confidence The document is a notice of an upcoming 기업설명회 (IR) event, listing the date, time, participants, content overview, and webcast details. This corresponds to an investor presentation announcement rather than actual financial statements or voting results. It matches the definition of an Investor Presentation (Code: IP).
2026-05-14 Korean
기업설명회(IR)개최
Regulatory Filings Classification · 80% confidence The document is a brief announcement in Korean of an upcoming investor relations presentation (IR event) with dates, times, audience, purpose, and webcast link. It does not contain the actual presentation materials or financial statements, nor is it a formal interim or annual report. It is not a proxy statement, earnings release, or dividend notice. It is essentially an event disclosure, best classified as a general regulatory filing (RNS) under our taxonomy for miscellaneous regulatory announcements.
2026-05-14 Korean
투자판단관련주요경영사항(임상시험계획승인신청등결정) (CLDN18.2 항체-약물 접합체 (ADC) LCB02A의 제 1/2상 임상시험의 미국 임상시험계획(IND) 승인)
Regulatory Filings Classification · 65% confidence The document is a Korean stock exchange disclosure titled “투자판단 관련 주요경영사항(임상시험 계획 승인 등 결정)” detailing FDA IND approval for a Phase 1/2 clinical trial. It is a material event announcement about business developments, with no financial statements, earnings data, or meeting materials. It fits none of the specific report types (10-K, IR, ER, IP, etc.) and is essentially a regulatory announcement of a material corporate event. Therefore, it defaults to “Regulatory Filings (RNS).”
2026-05-14 Korean
대표이사변경
Board/Management Information Classification · 90% confidence The document announces the resignation of the former CEO and the appointment of a new representative director, including board resolution dates and executive’s career details. This is clearly an announcement of changes in senior management, fitting the Board/Management Information category.
2026-04-29 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.